World Pharma News Digest - 22.07.2014
21 views
Skip to first unread message
Ruslan David
Jul 22, 2014, 8:50:43 AM7/22/14
to worldph...@googlegroups.com
Health IT Space Business Social Network (Europe)
You are kindly invited to explore the beta version of the first business social networking platform for Health IT Professionals, named Health IT Space (Europe):
Read more...
http://www.healthitspace.eu
MedImmune and Advaxis partner on immuno-oncology combination clinical trial
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies.
Read more...
http://www.worldpharmanews.com/astrazeneca/2835-medimmune-and-advaxis-partner-on-immuno-oncology-combination-clinical-trial
Niacin too dangerous for routine cholesterol therapy
After 50 years of being a mainstay cholesterol therapy, niacin should no longer be prescribed for most patients due to potential increased risk of death, dangerous side effects and no benefit in reducing heart attacks and strokes, writes Northwestern Medicine® preventive cardiologist Donald Lloyd-Jones, M.D., in a New England Journal of Medicine editorial.
Read more...
http://www.worldpharmanews.com/research/2834-niacin-too-dangerous-for-routine-cholesterol-therapy
AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK
AstraZeneca today revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK. The plans for the new facility, which will be located on the Cambridge Biomedical Campus (CBC), include designs for the Global Centre, an R&D Enabling Building and an Energy Centre(1).
Read more...
http://www.worldpharmanews.com/astrazeneca/2833-astrazeneca-reveals-designs-for-new-global-rad-centre-and-corporate-headquarters-in-cambridge-uk
Novartis maintained strong innovation momentum in second quarter
Novartis Group net sales increased 2% (+2% cc) to USD 14.6 billion in the second quarter. Growth products contributed USD 4.7 billion or 32% of Group net sales, up 18% (USD) over the prior-year quarter. Group operating income increased 6% (+11% cc) to USD 3.1 billion. Currency had a negative impact of 5 percentage points, primarily due to the stronger Swiss franc and weakening of emerging market currencies, partly offset by a stronger euro.
Read more...
http://www.worldpharmanews.com/novartis/2832-novartis-maintained-strong-innovation-momentum-in-second-quarter
Pfizer to Acquire InnoPharma, Inc.
Pfizer Inc. (NYSE:PFE) and InnoPharma, Inc., a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will acquire InnoPharma.
Read more...
http://www.worldpharmanews.com/pfizer/2831-pfizer-to-acquire-innopharma-inc
Taking B vitamins won't prevent Alzheimer's disease
Taking B vitamins doesn't slow mental decline as we age, nor is it likely to prevent Alzheimer's disease, conclude Oxford University researchers who have assembled all the best clinical trial data involving 22,000 people to offer a final answer on this debate. High levels in the blood of a compound called homocysteine have been found in people with Alzheimer's disease, and people with higher levels of homocysteine have been shown to be at increased risk of Alzheimer's disease.
Read more...
http://www.worldpharmanews.com/research/2830-taking-b-vitamins-wont-prevent-alzheimers-disease
Novartis to license Google "smart lens" technology
Novartis announced that its eye care division Alcon has entered into an agreement with a division of Google Inc. to in-license its "smart lens" technology for all ocular medical uses. The agreement with Google[x], a team within Google that is devoted to finding new solutions to big global problems,
Read more...
http://www.worldpharmanews.com/novartis/2829-novartis-to-license-google-qsmart-lensq-technology
Abbott to sell its developed markets branded generics pharmaceuticals business to Mylan
Abbott (NYSE: ABT) announced today that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company.
Read more...
http://www.worldpharmanews.com/abbott/2828-abbott-to-sell-its-developed-markets-branded-generics-pharmaceuticals-business-to-mylan
PharmaNews.eu / Latest News
Scientists map one of most important proteins in life - and cancer
http://www.pharmanews.eu/research-and-development/1461-scientists-map-one-of-most-important-proteins-in-life-and-cancer
Taking B vitamins won't prevent Alzheimer's disease
http://www.pharmanews.eu/research-and-development/1458-taking-b-vitamins-wont-prevent-alzheimers-disease
New research reveals how cannabis compound could slow tumour growth
http://www.pharmanews.eu/research-and-development/1460-new-research-reveals-how-cannabis-compound-could-slow-tumour-growth
European Medicines Agency recommends 39 medicines for human use for marketing authorisation in first half of 2014
http://www.pharmanews.eu/ema/1459-european-medicines-agency-recommends-39-medicines-for-human-use-for-marketing-authorisation-in-first-half-of-2014
Safer, cheaper building blocks for future anti-HIV and cancer drugs
http://www.pharmanews.eu/research-and-development/1457-safer-cheaper-building-blocks-for-future-anti-hiv-and-cancer-drugs
MRC Technology and AstraZeneca renew collaboration to identify novel targets for discovery research
http://www.pharmanews.eu/research-and-development/1456-mrc-technology-and-astrazeneca-renew-collaboration-to-identify-novel-targets-for-discovery-research
Artificial bone material wins major award and moves nearer to patient use
http://www.pharmanews.eu/research-and-development/1455-artificial-bone-material-wins-major-award-and-moves-nearer-to-patient-use
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
Health IT Space, http://www.healthitspace.eu
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
You are kindly invited to explore the beta version of the first business social networking platform for Health IT Professionals, named Health IT Space (Europe):
Read more...
http://www.healthitspace.eu
MedImmune and Advaxis partner on immuno-oncology combination clinical trial
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies.
Read more...
http://www.worldpharmanews.com/astrazeneca/2835-medimmune-and-advaxis-partner-on-immuno-oncology-combination-clinical-trial
Niacin too dangerous for routine cholesterol therapy
After 50 years of being a mainstay cholesterol therapy, niacin should no longer be prescribed for most patients due to potential increased risk of death, dangerous side effects and no benefit in reducing heart attacks and strokes, writes Northwestern Medicine® preventive cardiologist Donald Lloyd-Jones, M.D., in a New England Journal of Medicine editorial.
Read more...
http://www.worldpharmanews.com/research/2834-niacin-too-dangerous-for-routine-cholesterol-therapy
AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK
AstraZeneca today revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK. The plans for the new facility, which will be located on the Cambridge Biomedical Campus (CBC), include designs for the Global Centre, an R&D Enabling Building and an Energy Centre(1).
Read more...
http://www.worldpharmanews.com/astrazeneca/2833-astrazeneca-reveals-designs-for-new-global-rad-centre-and-corporate-headquarters-in-cambridge-uk
Novartis maintained strong innovation momentum in second quarter
Novartis Group net sales increased 2% (+2% cc) to USD 14.6 billion in the second quarter. Growth products contributed USD 4.7 billion or 32% of Group net sales, up 18% (USD) over the prior-year quarter. Group operating income increased 6% (+11% cc) to USD 3.1 billion. Currency had a negative impact of 5 percentage points, primarily due to the stronger Swiss franc and weakening of emerging market currencies, partly offset by a stronger euro.
Read more...
http://www.worldpharmanews.com/novartis/2832-novartis-maintained-strong-innovation-momentum-in-second-quarter
Pfizer to Acquire InnoPharma, Inc.
Pfizer Inc. (NYSE:PFE) and InnoPharma, Inc., a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will acquire InnoPharma.
Read more...
http://www.worldpharmanews.com/pfizer/2831-pfizer-to-acquire-innopharma-inc
Taking B vitamins won't prevent Alzheimer's disease
Taking B vitamins doesn't slow mental decline as we age, nor is it likely to prevent Alzheimer's disease, conclude Oxford University researchers who have assembled all the best clinical trial data involving 22,000 people to offer a final answer on this debate. High levels in the blood of a compound called homocysteine have been found in people with Alzheimer's disease, and people with higher levels of homocysteine have been shown to be at increased risk of Alzheimer's disease.
Read more...
http://www.worldpharmanews.com/research/2830-taking-b-vitamins-wont-prevent-alzheimers-disease
Novartis to license Google "smart lens" technology
Novartis announced that its eye care division Alcon has entered into an agreement with a division of Google Inc. to in-license its "smart lens" technology for all ocular medical uses. The agreement with Google[x], a team within Google that is devoted to finding new solutions to big global problems,
Read more...
http://www.worldpharmanews.com/novartis/2829-novartis-to-license-google-qsmart-lensq-technology
Abbott to sell its developed markets branded generics pharmaceuticals business to Mylan
Abbott (NYSE: ABT) announced today that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company.
Read more...
http://www.worldpharmanews.com/abbott/2828-abbott-to-sell-its-developed-markets-branded-generics-pharmaceuticals-business-to-mylan
PharmaNews.eu / Latest News
Scientists map one of most important proteins in life - and cancer
http://www.pharmanews.eu/research-and-development/1461-scientists-map-one-of-most-important-proteins-in-life-and-cancer
Taking B vitamins won't prevent Alzheimer's disease
http://www.pharmanews.eu/research-and-development/1458-taking-b-vitamins-wont-prevent-alzheimers-disease
New research reveals how cannabis compound could slow tumour growth
http://www.pharmanews.eu/research-and-development/1460-new-research-reveals-how-cannabis-compound-could-slow-tumour-growth
European Medicines Agency recommends 39 medicines for human use for marketing authorisation in first half of 2014
http://www.pharmanews.eu/ema/1459-european-medicines-agency-recommends-39-medicines-for-human-use-for-marketing-authorisation-in-first-half-of-2014
Safer, cheaper building blocks for future anti-HIV and cancer drugs
http://www.pharmanews.eu/research-and-development/1457-safer-cheaper-building-blocks-for-future-anti-hiv-and-cancer-drugs
MRC Technology and AstraZeneca renew collaboration to identify novel targets for discovery research
http://www.pharmanews.eu/research-and-development/1456-mrc-technology-and-astrazeneca-renew-collaboration-to-identify-novel-targets-for-discovery-research
Artificial bone material wins major award and moves nearer to patient use
http://www.pharmanews.eu/research-and-development/1455-artificial-bone-material-wins-major-award-and-moves-nearer-to-patient-use
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
Health IT Space, http://www.healthitspace.eu
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
Reply all
Reply to author
Forward
0 new messages